After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Vanda Pharmaceuticals Inc. (VNDA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.36, or -4.87%, to $7.03. The Vanda Pharmaceuticals Inc. has recorded 13,233 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study.
VNDA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $7.39 and fluctuated between $7.41 as its day high and $7.24 as its day low. The current market capitalization of Vanda Pharmaceuticals Inc. is $413.10M. A total of 0.53 million shares were traded on the day, compared to an average of 571.88K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, VNDA has seen 3 BUY and 3 SELL insider trades, representing the acquisition of 157,500 and the disposition of 100,692 shares. Over the last 12 months, there were 15 BUYs and 18 SELLs from insiders. Insiders purchased 482,574 shares during that period but sold 214,513.
In the most recent transaction, Williams Timothy sold 8,000 shares of VNDA for 7.01 per share on Dec 15. After the transaction, the SVP & General Counsel now owns 87,551 company shares. In a previous transaction on Dec 06, Polymeropoulos Mihael Hristos sold 48,250 shares at 10.61 per share. VNDA shares that President and CEO owns now total 1,406,866.
Among the insiders who sold shares, Moran Kevin Patrick disposed of 4,792 shares on Dec 06 at a per-share price of $10.61. This resulted in the SVP, CFO & Treasurer holding 120,160 shares of VNDA after the transaction. In another insider transaction, Polymeropoulos Mihael Hristos sold 47,650 shares at $10.62 per share on Dec 05. Company shares held by the President and CEO now total 1,379,751.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for VNDA in the last 3 months, the mean price target is $11.00 with high estimates of $11.00 and low estimates of $11.00. In terms of 52-week highs and lows, VNDA has a high of $16.92 and a low of $6.73.
As of this writing, VNDA has an earnings estimate of $0.09 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of $0.09 per share and a lower estimate of $0.09. The company reported an EPS of -$0.11 in the last quarter, which was -1,000.00% lower than expectations of -$0.01.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VNDA is Buy with a score of 3.00. A total of 0 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.